{
  "metadata": {
    "export_date": "2026-01-05T06:58:20.793509",
    "patient_profile": {
      "age": 71,
      "sex": "male",
      "cancer_type": "squamous cell lung cancer",
      "biomarkers": [],
      "description": "71-year-old male with metastatic squamous cell lung cancer, no actionable driver mutations identified (EGFR/ALK/ROS1/BRAF wild-type, KRAS wild-type). PD-L1 TPS \u226590%. First-line pembrolizumab monotherapy achieved durable response for 22 months, now progressed with new contralateral lung nodules and mediastinal lymphadenopathy. Seeking second-line immunotherapy combinations or novel checkpoint approaches. Former heavy smoker (50 pack-years). COPD on inhalers, no supplemental O2. Mild CKD (eGFR 52). Motivated patient willing to travel for trials."
    },
    "total_trials": 100,
    "high_likelihood": 0,
    "medium_likelihood": 1
  },
  "results": [
    {
      "nct_id": "NCT06403436",
      "title": "A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors",
      "sponsor": "TOLREMO therapeutics AG",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "MEDIUM",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Patient is male and \u2265 18 years old",
        "Patient has a squamous cell lung cancer",
        "ECOG status of 1",
        "Patient has advanced solid tumors that have progressed after prior treatment"
      ],
      "conflicts": [],
      "uncertainties": [
        "Laboratory values for adequate hematological, hepatic, and renal function are not provided",
        "Patient's life expectancy not explicitly stated"
      ],
      "confidence": 0.65,
      "reasoning": "The patient's cancer type matches the trial conditions as he has squamous cell lung cancer. He is a previously treated patient, which is acceptable according to trial criteria. However, there are uncertainties regarding organ function labs and life expectancy that need verification for a conclusive eligibility assessment.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT05566223",
      "title": "A Phase 1/2 Trial (CheckCell-2) in Patients With Metastatic Non-small Cell Lung Cancer (NSCLC) Administering Tumor-Infiltrating Lymphocytes (TILs) in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System",
      "sponsor": "Intima Bioscience, Inc.",
      "phase": "Phase 1/Phase 2",
      "status": "Not yet recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Confirmed histologic diagnosis of squamous cell lung cancer",
        "ECOG status of 1",
        "PD-L1 TPS \u226590%",
        "No actionable driver mutations identified"
      ],
      "conflicts": [
        "Age 71 does not meet the eligibility criterion of age \u2264 70 years."
      ],
      "uncertainties": [
        "Hematologic and organ function lab values are not provided.",
        "No information on serology testing results.",
        "No information regarding potential ongoing infections."
      ],
      "confidence": 0.1,
      "reasoning": "The patient's cancer type matches the trial indication; however, the age criterion is not met, leading to exclusion.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT03476681",
      "title": "Phase 1/2 With Expansion Cohorts in a Study of NEO-201 in Adults With Chemo-Resistant Solid Tumors",
      "sponsor": "Precision Biologics, Inc",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT03586453",
      "title": "A Phase II Study of Osimertinib With On-study and Post-progression Biopsy in the First Line Treatment of EGFR Inhibitor na\u00efve Advanced EGFR Mutant Lung Cancer",
      "sponsor": "Dana-Farber Cancer Institute",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT04093167",
      "title": "A Biomarker-Directed, Multi-Centre Phase II/III Study of CTDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung Cancer",
      "sponsor": "Canadian Cancer Trials Group",
      "phase": "Phase 2/Phase 3",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT04130516",
      "title": "A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer With and Without Pembrolizumab",
      "sponsor": "Linnaeus Therapeutics, Inc.",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT04253964",
      "title": "Phase II Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-Small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy",
      "sponsor": "Wake Forest University Health Sciences",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT04300556",
      "title": "A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FR\u03b1)-Targeting Antibody-drug Conjugate (ADC) in Subjects With Selected Tumor Types",
      "sponsor": "Eisai Inc.",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT04317534",
      "title": "A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153",
      "sponsor": "Greg Durm, MD",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT04486833",
      "title": "A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination With Osimertinib in Patients With Advanced, Metastatic EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer",
      "sponsor": "Genprex, Inc.",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT04499053",
      "title": "A Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer",
      "sponsor": "Georgetown University",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT04585477",
      "title": "Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)",
      "sponsor": "Stanford University",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT04868877",
      "title": "Phase 1/2 Dose Escalation and Expansion Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors",
      "sponsor": "Merus N.V.",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT04892953",
      "title": "Local Consolidative Therapy (LCT) and Durvalumab (MEDI4736) for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy (ENDURE)",
      "sponsor": "M.D. Anderson Cancer Center",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT04991025",
      "title": "Phase 2 Trial of Neoadjuvant Nivolumab + Platinum-based Chemotherapy + Certolizumab in Patients With Resectable Stages II-III Lung Cancers",
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT05094336",
      "title": "A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors",
      "sponsor": "Amgen",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT05098132",
      "title": "A Phase 1/2 Study to Evaluate STK-012 as a Single Agent and in Combination Therapy in Subjects With Front-line Advanced NSCLC and Other Selected Indications",
      "sponsor": "Synthekine",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT05118854",
      "title": "A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation",
      "sponsor": "M.D. Anderson Cancer Center",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT05121051",
      "title": "Phase II Randomized, Double Blind, Placebo-Controlled Trial of Broccoli Seed and Sprout Extract (BSSE), Avmacol ES, to Evaluate Sustained Detoxification of Tobacco Carcinogens in Heavy Smokers",
      "sponsor": "National Cancer Institute (NCI)",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT05123482",
      "title": "A Phase I/IIa Multi-center, Open-label Master Protocol Dose Escalation and Expansion Study of AZD8205 as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors (BLUESTAR)",
      "sponsor": "AstraZeneca",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT05168566",
      "title": "A Multicenter, Open-label, Phase IIb Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X, and/or S768I)",
      "sponsor": "Teligene US",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT05261399",
      "title": "A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON).",
      "sponsor": "AstraZeneca",
      "phase": "Phase 3",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT05267626",
      "title": "A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R\u03b1 Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer",
      "sponsor": "Aulos Bioscience, Inc.",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT05419375",
      "title": "Master Screening Study to Determine Biomarker Status and Potential Trial Eligibility for Patients With Malignant Tumors",
      "sponsor": "Hoffmann-La Roche",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT05500092",
      "title": "An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer",
      "sponsor": "Montefiore Medical Center",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT05584670",
      "title": "A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy or in Combination With Other Anticancer Therapies in Adults With Advanced Solid Tumors",
      "sponsor": "Sanofi",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT05642572",
      "title": "A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib With or Without Ramucirumab in Participants With EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)",
      "sponsor": "SWOG Cancer Research Network",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT05669846",
      "title": "Phase II Feasibility Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC",
      "sponsor": "Diwakar Davar",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT05715229",
      "title": "A Multicenter Phase II Randomized Trial Of Immunotherapy Versus Chemotherapy Guided By Circulating Tumor DNA-Based Molecular Response On Patients With Metastatic NSCLC",
      "sponsor": "Hackensack Meridian Health",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT05785741",
      "title": "A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1310 in Subjects With Advanced/Metastatic Solid Tumors",
      "sponsor": "DualityBio Inc.",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT05845671",
      "title": "A Phase 1 / 2, Open Label, Study of Amivantamab (JNJ-61186372) Among Participants With Advanced NSCLC Harboring ALK, ROS1, and RET Gene Fusions in Combination With Tyrosine Kinase Inhibitors",
      "sponsor": "University of Colorado, Denver",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT05887492",
      "title": "A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of TNG260 as Single Agent and in Combination With an Anti-PD-1 Antibody In Patients With STK11 Mutated Advanced Solid Tumors",
      "sponsor": "Tango Therapeutics, Inc.",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT05892068",
      "title": "Window of Opportunity Analysis of Pre-Operative Tucatinib for Surgically Resected HER2+ Brain Metastases: Understanding Mechanisms of Resistance",
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Trial requires female patients"
    },
    {
      "nct_id": "NCT06033196",
      "title": "Targeting Inflammation and Alloimmunity in Lung Transplant Recipients With Tocilizumab (CTOT-45)",
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06050707",
      "title": "MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach",
      "sponsor": "University Health Network, Toronto",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06090266",
      "title": "A Phase 1/2 Study of OR502 Alone and in Combination With Other Anti-cancer Agents in Subjects With Advanced Malignancies",
      "sponsor": "OncoResponse, Inc.",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06116682",
      "title": "A Phase II Study of Amivantamab SC (Subcutaneous) in Participants With MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)",
      "sponsor": "SWOG Cancer Research Network",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06151574",
      "title": "Beamion LUNG 2: A Phase III, Open-label, Randomized, Active-controlled, Multi-centre Trial Evaluating Orally Administered Zongertinib (BI 1810631) Compared With Standard of Care as First-line Treatment in Patients With Unresectable, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Harbouring HER2 Tyrosine Kinase Domain Mutations",
      "sponsor": "Boehringer Ingelheim",
      "phase": "Phase 3",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06236438",
      "title": "A Randomized, Phase 2/3 Study to Evaluate the Optimal Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)",
      "sponsor": "AbbVie",
      "phase": "Phase 2/Phase 3",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06265285",
      "title": "Pilot Single-Arm, Pragmatic Trial of In-Home Versus In-Clinic Subcutaneous Nivolumab Administration Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program",
      "sponsor": "Mayo Clinic",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06305754",
      "title": "A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors",
      "sponsor": "Merck Sharp & Dohme LLC",
      "phase": "Phase 3",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06311721",
      "title": "A Randomized, Double-Blind Study to Compare Efficacy, Pharmacokinetics, Safety, and Immunogenicity Between ABP 234 and Keytruda\u00ae (Pembrolizumab) in Subjects With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer",
      "sponsor": "Amgen",
      "phase": "Phase 3",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06312137",
      "title": "A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery",
      "sponsor": "Merck Sharp & Dohme LLC",
      "phase": "Phase 3",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06385262",
      "title": "Safety, Efficacy, and Tumor Immune Microenvironment Changes With Neoadjuvant Chemotherapy and Cemiplimab With or Without Alirocumab in Stage 1B-3A Non-Small Cell Lung Cancer: TOP 2301",
      "sponsor": "Duke University",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06422143",
      "title": "Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer",
      "sponsor": "Merck Sharp & Dohme LLC",
      "phase": "Phase 3",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06463665",
      "title": "A Randomized Phase 2 Study Assessing the Efficacy and Safety of Olvimulogene Nanivacirepvec Followed by Platinum-doublet Chemotherapy + Physician's Choice of Immune Checkpoint Inhibitor Compared With Docetaxel in Patients With NSCL Cancer After First Progression While on Front-line Immune Checkpoint Inhibitor-based Maintenance",
      "sponsor": "Genelux Corporation",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06472245",
      "title": "A Randomised, Open-label, Phase 3 Trial Comparing the Efficacy and Safety of OSE2101 Versus Docetaxel in HLA-A2 Positive Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) With Secondary Resistance to Immune Checkpoint Inhibitor",
      "sponsor": "OSE Immunotherapeutics",
      "phase": "Phase 3",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06561386",
      "title": "A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression \u2265 1%",
      "sponsor": "Bristol-Myers Squibb",
      "phase": "Phase 3",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06568939",
      "title": "A Phase 2, Open-Label, Randomized, Global Study of Three Telisotuzumab Vedotin Regimens in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer",
      "sponsor": "AbbVie",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06593522",
      "title": "A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 193 in Subjects With Methylthioadenosine Phosphorylase (MTAP)-Deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)",
      "sponsor": "Amgen",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06627647",
      "title": "A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)",
      "sponsor": "AstraZeneca",
      "phase": "Phase 3",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06657222",
      "title": "A Multicenter FIH Dose Escalation and Optimization Phase I/IIa Trial to Investigate Safety, Tolerability, PK, and Efficacy of the 5T4 ADC TUB-030 in Patients With Advanced Solid Tumors (5-STAR 1-01)",
      "sponsor": "Tubulis GmbH",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06695845",
      "title": "A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)",
      "sponsor": "Jazz Pharmaceuticals",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06780085",
      "title": "KEYMAKER-U01 Substudy 01H: A Phase 2, Randomized, Umbrella Study With Rolling Arms of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC)",
      "sponsor": "Merck Sharp & Dohme LLC",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06780098",
      "title": "KEYMAKER-U01 Substudy 01I: A Phase 2, Randomized, Umbrella Study With Rolling Arms of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC)",
      "sponsor": "Merck Sharp & Dohme LLC",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06814496",
      "title": "RAdiation comBined With BIspecific T-Cell Engager in DLL3 Expressing Tumors (RABBIT) Study: A Phase I/II Study of AMG757 / Tarlatamab and Concurrent Radiation Therapy in Tumors With High Prevalence of DLL3",
      "sponsor": "University of Arizona",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06875310",
      "title": "A Randomized, Double-Blind, Phase 3 Trial of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)",
      "sponsor": "Mirati Therapeutics Inc.",
      "phase": "Phase 3",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06933329",
      "title": "Phase 2 Study of Zelenectide Pevedotin in Participants With Previously-Treated NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer",
      "sponsor": "BicycleTx Limited",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06973564",
      "title": "A Phase 1/2a, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of JAB-23E73 in Adult Patients With Advanced Solid Tumors With KRAS Alteration",
      "sponsor": "Jacobio Pharmaceuticals Co., Ltd.",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06975293",
      "title": "Open-label, Non-randomized, Multi-cohort, Phase 1b/2 Trial Investigating the Safety, Tolerability, and Antitumor Activity of STC-15 (a METTL3 Inhibitor) as a Part of Combination Therapy With Toripalimab in Participants With Selected Advanced Cancers",
      "sponsor": "STORM Therapeutics LTD",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06996782",
      "title": "A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer",
      "sponsor": "AstraZeneca",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT07005102",
      "title": "A Phase 2/3 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer",
      "sponsor": "AbbVie",
      "phase": "Phase 2/Phase 3",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT07132918",
      "title": "The cARdiac Radiation Therapy Sparing (HEARTS) for Thoracic Cancers",
      "sponsor": "University of Wisconsin, Madison",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT00068003",
      "title": "Cell Harvest and Preparation for Surgery Branch Treatment Protocols",
      "sponsor": "National Cancer Institute (NCI)",
      "phase": null,
      "status": "Enrolling by invitation",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT00900419",
      "title": "Biomarkers and Dysplastic Respiratory Epithelium",
      "sponsor": "University of Colorado, Denver",
      "phase": null,
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT02178163",
      "title": "A Study to Assess the Ability to Initiate Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Patients Based on Genomic Analyses of Tumor Specimens.",
      "sponsor": "Barbara Ann Karmanos Cancer Institute",
      "phase": "Not Applicable",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT02596490",
      "title": "Couple-Based Meditation for Metastatic Lung Cancer Patients and Their Partners",
      "sponsor": "M.D. Anderson Cancer Center",
      "phase": "Not Applicable",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT03740256",
      "title": "A First in Human Phase I Trial of Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR T Cells in Patients With Advanced HER2 Positive Solid Tumors",
      "sponsor": "Baylor College of Medicine",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT03774758",
      "title": "Circulating Tumor DNA for Risk Stratification in Lung Cancer Screening",
      "sponsor": "University of California, San Francisco",
      "phase": null,
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT03948100",
      "title": "Dyadic Behavioral Interventions to Manage Physical Performance, Symptoms and Quality of Life for Patient Undergoing Radiotherapy and Their Family Caregivers",
      "sponsor": "M.D. Anderson Cancer Center",
      "phase": "Not Applicable",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT03987555",
      "title": "Pilot Feasibility Study of Paclitaxel Therapeutic Drug Monitoring in Cancer Patients",
      "sponsor": "Wake Forest University Health Sciences",
      "phase": null,
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT04119024",
      "title": "Phase I Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma and Other Solid Tumors",
      "sponsor": "Anusha Kalbasi",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT04165798",
      "title": "KEYMAKER-U01 Master Study: A Phase 1/2, Umbrella Study With Rolling Arms of Investigational Agents, Pembrolizumab, and Chemotherapy, Alone or in Combination, in Participants With Non-small Cell Lung Cancer (NSCLC)",
      "sponsor": "Merck Sharp & Dohme LLC",
      "phase": null,
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT04429542",
      "title": "First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGF\u03b2 Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors",
      "sponsor": "Bicara Therapeutics",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT04762199",
      "title": "A Phase 1b Safety and Pharmacodynamic Study of MER Tyrosine Kinase Inhibitor, MRX-2843, in Combination With Osimertinib in Advanced EGFR Mutant Non-Small Cell Lung Cancer",
      "sponsor": "Emory University",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT04777994",
      "title": "A Phase 1 Study With ABBV-CLS-484 Alone and in Combination in Subjects With Locally Advanced or Metastatic Tumors",
      "sponsor": "Calico Life Sciences LLC",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT05005403",
      "title": "A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors With Azirkitug (ABBV-514) as a Single Agent and in Combination With Budigalimab or Bevacizumab",
      "sponsor": "AbbVie",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT05059444",
      "title": "ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation",
      "sponsor": "Guardant Health, Inc.",
      "phase": null,
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT05076760",
      "title": "Phase I Study Evaluating MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors",
      "sponsor": "Memgen, Inc.",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT05277051",
      "title": "A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Selected Advanced Solid Tumors",
      "sponsor": "GlaxoSmithKline",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT05332925",
      "title": "Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC (TUMORIN)",
      "sponsor": "Jun Zhang, MD, PhD",
      "phase": null,
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT05514717",
      "title": "A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-2056 in Participants With Advanced/Recurrent Solid Tumors That Express HER2",
      "sponsor": "Mersana Therapeutics",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT05520099",
      "title": "Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)",
      "sponsor": "Elephas",
      "phase": null,
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT05720117",
      "title": "A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants With Advanced Solid Tumors",
      "sponsor": "Pyxis Oncology, Inc",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT05815173",
      "title": "Phase I/II Study of Ladarixin and Sotorasib in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)",
      "sponsor": "NYU Langone Health",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT05827614",
      "title": "An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Dose-Expansion, Phase 1/2 Study of BBI-355 and BBI-355 in Combination With Select Targeted Therapies in Subjects With Locally Advanced or Metastatic Solid Tumors With Oncogene Amplifications",
      "sponsor": "Boundless Bio",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT05853887",
      "title": "iNUDGE: INtegration of liqUiD Biopsy Based Next Generation Gene sEquencing in Newly Diagnosed NSCLC - A Stepped Wedge Cluster Randomized Clinical Trial",
      "sponsor": "Charu Aggarwal",
      "phase": "Not Applicable",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06124118",
      "title": "A Feasibility Study to Evaluate the Addition of Tumor Treating Fields to Treatment of Locally Advanced Stage III NSCLC",
      "sponsor": "University of Utah",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06225804",
      "title": "A Phase 1, Open-Label Study of ABSK112 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Non-Small Cell Lung Cancer",
      "sponsor": "Abbisko Therapeutics Co, Ltd",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06252129",
      "title": "Maximizing Lymph Node Dissection on Fresh and Fixed Lung Cancer Resection Specimens",
      "sponsor": "Brigham and Women's Hospital",
      "phase": "Not Applicable",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06253871",
      "title": "A Phase 1/1b Study of IAM1363 in Patients With Advanced Cancers Harboring HER2 Alterations",
      "sponsor": "Iambic Therapeutics, Inc",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06400472",
      "title": "A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor \u03b1-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors",
      "sponsor": "Eli Lilly and Company",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06427941",
      "title": "A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Selected Advanced or Metastatic Solid Tumors",
      "sponsor": "BeOne Medicines",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06465069",
      "title": "A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors",
      "sponsor": "Eli Lilly and Company",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06545331",
      "title": "A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors",
      "sponsor": "Exelixis",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06548672",
      "title": "A Phase Ia/Ib, Open-Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC3195 in Patients With Locally Advanced or Metastatic Solid Tumors",
      "sponsor": "Biocity Biopharmaceutics Co., Ltd.",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06566443",
      "title": "Phase I Trial Evaluating the Safety of the Dietary Supplement Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer",
      "sponsor": "The Methodist Hospital Research Institute",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06671613",
      "title": "Evaluating the Impact of Intermittent Fasting in Combination With Checkpoint Inhibitors in Patients With Non-small Cell Lung Cancer",
      "sponsor": "VA Office of Research and Development",
      "phase": "Not Applicable",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06712745",
      "title": "Feasibility Study of Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for Cancers of the Central Lung",
      "sponsor": "University of Texas Southwestern Medical Center",
      "phase": "Early Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT07073183",
      "title": "A Phase I Dose-Finding Study to Evaluate Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC)",
      "sponsor": "CureVac",
      "phase": "Phase 1",
      "status": "Not yet recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    }
  ]
}